{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:20:08Z","timestamp":1791973208340,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.bone.2011.04.014","type":"journal-article","created":{"date-parts":[[2011,5,2]],"date-time":"2011-05-02T04:35:49Z","timestamp":1304310949000},"page":"281-289","source":"Crossref","is-referenced-by-count":39,"title":["The skeletal effects of the tyrosine kinase inhibitor nilotinib"],"prefix":"10.1016","volume":"49","author":[{"given":"Susannah","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Callon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak Cheung","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Naot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opetaia","family":"Aati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Porteous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Browett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2011.04.014_bb0005","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bone.2011.04.014_bb0010","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","article-title":"Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit","volume":"30","author":"Verstovsek","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.bone.2011.04.014_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bone.2011.04.014_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bone.2011.04.014_bb0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.leu.2404944","article-title":"Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis","volume":"22","author":"Brownlow","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2011.04.014_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1209007","article-title":"FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance","volume":"25","author":"Taylor","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bone.2011.04.014_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bone.2011.04.014_bb0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bone.2011.04.014_bb0045","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2011.04.014_bb0050","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.014_bb0055","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2009.04.030","article-title":"Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib","volume":"45","author":"Montemurro","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bone.2011.04.014_bb0060","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2011.04.014_bb0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2011.04.014_bb0070","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.014_bb0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bone.2011.04.014_bb0080","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.014_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1711.2004.01296.x","article-title":"Imatinib inhibits the functional capacity of cultured human monocytes","volume":"83","author":"Dewar","year":"2005","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.bone.2011.04.014_bb0090","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2403071","article-title":"Imatinib inhibits the in vitro development of the monocyte\/macrophage lineage from normal human bone marrow progenitors","volume":"17","author":"Dewar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2011.04.014_bb0095","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2011.04.014_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bone.2011.04.014_bb0105","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.014_bb0110","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"Jonsson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2011.04.014_bb0115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","article-title":"Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib","volume":"94","author":"O'Sullivan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.014_bb0120","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.014_bb0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMc061565","article-title":"Imatinib and altered bone and mineral metabolism","volume":"355","author":"Owen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.014_bb0130","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2011.04.014_bb0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptor\u03b2 by imatinib mesylate suppresses proliferation and alters differentiation of human mesencymal stem cells in vitro","volume":"40","author":"Fierro","year":"2007","journal-title":"Cell Prolif"},{"key":"10.1016\/j.bone.2011.04.014_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","article-title":"Effects of imatinib mesylate in osteoblastogenesis","volume":"37","author":"Tibullo","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bone.2011.04.014_bb0145","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s10495-006-9507-z","article-title":"Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor","volume":"11","author":"Gallet","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.bone.2011.04.014_bb0150","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1210\/endo.142.3.8011","article-title":"Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42\/44 mitogen-activated protein kinases","volume":"142","author":"Grey","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2011.04.014_bb0155","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0309-1651(85)90015-3","article-title":"Osteocalcin antigenicity in cultured osteoblast-like cells after stimulation with 1,25-vitamin D3","volume":"9","author":"Groot","year":"1985","journal-title":"Cell Biol Int Rep"},{"key":"10.1016\/j.bone.2011.04.014_bb0160","series-title":"The effect of PTH and PGE2 on growth and differentiation of primary fetal rat osteblast-like cells, on UMR 106 osteosarcoma cells, and on a SV40 transformed \u201costeoblast-like\u201d cell line","year":"1986"},{"key":"10.1016\/j.bone.2011.04.014_bb0165","first-page":"E827","article-title":"Dissociation of the effects of amylin on osteoblast proliferation and bone resorption","volume":"274","author":"Cornish","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bone.2011.04.014_bb0170","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1210\/en.2003-0350","article-title":"Parallel phosphatidylinositol-3 kinase and p42\/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells","volume":"144","author":"Grey","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2011.04.014_bb0175","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1359\/JBMR.051104","article-title":"Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL","volume":"21","author":"Middleton-Hardie","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.014_bb0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0009-8981(77)90059-6","article-title":"A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man","volume":"81","author":"Walton","year":"1977","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bone.2011.04.014_bb0185","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","article-title":"The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial","volume":"92","author":"Grey","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.014_bb0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.014_bb0195","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/73542","article-title":"Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation","volume":"24","author":"Li","year":"2000","journal-title":"Nat Genet"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211009367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211009367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T12:18:41Z","timestamp":1560169121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328211009367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S8756328211009367"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.04.014","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}